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ABSTRACT 35 
Menopause is associated with bone loss and visceral adiposity.  Although 36 
estrogen prevents bone loss, its inhibitory effect on body fat is less consistent.  We 37 
questioned instead whether we could target a rising Fsh level during the 38 
perimenopausal transition with a single agent to increase bone mass and reduce body 39 
fat.  We previously showed that a polyclonal antibody (Ab) that binds to the β-subunit of 40 
Fsh and blocks its interaction with the Fsh receptor (Fshr) increases bone mass.  Here, 41 
we report that the Fsh Ab causes a marked reduction in visceral white adipose tissue 42 
(WAT) in mice fed a high fat diet, in ovariectomized mice, and interestingly, in mice on 43 
normal chow.  The global reduction in body fat, not seen in Fshr-/- mice that were 44 
similarly treated with Ab, was associated with profound beiging and brown adipose 45 
tissue (BAT) activation, noted most impressively in the ThermoMouse, in which Luc2 is 46 
driven by an Ucp1 promoter.  These changes were accompanied by increased indices 47 
of thermogenesis, namely energy expenditure, oxygen utilization and physical activity, 48 
as well as increased mitochondrial density noted in the PhAMexcised mouse.  We show 49 
that these actions result from the specific binding of Ab to Fshβ to block its action on 50 
full-length, signaling-efficient Fshrs abundantly expressed in adipocytes.  Our studies 51 
expose novel opportunities for treating both obesity and osteoporosis. 52 
  53 
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Fsh favors mammalian procreation by synthesizing and releasing estrogen from 54 
ovarian follicles, where Fsh receptors (Fshrs) are highly expressed.  However, it is not 55 
inconceivable that Fsh, through its action on the skeleton1, may also regulate 56 
intergenerational calcium transfer from the mother to mineralize the offspring’s skeleton.  57 
Whereas there is no evidence yet for this action, what is clear is that FSH levels 58 
become elevated as the ability to procreate ceases at menopause.  It is during the late 59 
perimenopause, a period characterized by relatively stable estrogen and rising FSH 60 
levels, that bone loss occurs at its most rapid rate2,3.  There is also a sharp increase in 61 
visceral adiposity during this life stage, which coincides with the emergence of disrupted 62 
energy balance and reduced physical activity4.  While the subsequent decline in 63 
estrogen explains menopausal bone loss in large part5, effects of estrogen deprivation 64 
on whole body metabolism remain unclear6.  We therefore questioned whether, by 65 
targeting FSH, we could not only prevent bone loss, but also reduce visceral adiposity 66 
and improve energy homeostasis. 67 
 68 
Fsh Ab Binds and Blocks Fsh Action in the Circulation 69 
Considering that Fshr activation on osteoclasts enhanced bone resorption and 70 
that Fsh haploinsufficiency in the Fshβ+/- mouse was associated with low resorption 71 
rates and high bone mass1, we raised a polyclonal antibody (Ab) to a 13-amino acid 72 
sequence of Fshβ (LVYKDPARPKIQK) that would, based on computational modeling, 73 
block Fsh binding to the Fshr1,7,8.  As predicted, we found that the Ab inhibited bone 74 
resorption, stimulated new bone synthesis and increased bone mass in ovariectomized 75 
mice7.  Here, we establish definitively that the Fsh Ab binds to and interrupts the 76 
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interaction of Fshβ with its receptor at concentrations well within the relevant circulating 77 
range. 78 
Recombinant mouse Fsh (Fshα-Fshβ chimera, 2 µg) was passed through resin 79 
(Pierce Co-Immunoprecipitation Kit) with immobilized Fsh Ab or goat IgG.  The elution, 80 
flow-through and wash fractions were then immunoblotted with a different Fsh Ab (Hf2).  81 
Figure 1A shows a band at the expected size, ~50 kD, in both elution and flow through 82 
fractions.  In contrast, the eluted fraction from immobilized IgG did not display a band; 83 
instead, all protein appeared in the flow through fraction (Figure 1A).  The Ab-84 
immunoprecipitated eluate was trypsinized and analyzed by liquid chromatography 85 
tandem mass spectrometry (LC MS/MS), which matched ten peptides corresponding to 86 
the Fshα-Fshβ chimera (Figure 1B, Extended Data Table 1).  This definitively 87 
established Fsh as the binding partner of the Ab. 88 
We questioned whether the binding of the Ab to the LVYKDPARPKIQK 89 
sequence of human Fshβ, against which it was raised7, could block the interaction of 90 
Fsh with the Fshr in mice.  For this, we used the crystal structure of the human FSH-91 
FSHR complex containing the LVYKDPARPKIQK sequence (PDB ID 4AY9) (Figure 92 
1Ci) to model mouse Fsh(LVYKDPARPNTQK)-Fshr interactions in silico (Figure 1Cii).  93 
Binding modes of the respective complexes were found to be identical (c.f. Figures 1Ci 94 
and 1Cii).  We further noted that the net positive charge of the peptide surface (blue 95 
residues) complements the overall negative charge of Fshr-binding surface (red 96 
residues), thus generating strong electrostatic interactions (Figure 1Ciii).  Furthermore, 97 
and importantly, the loop from Fshβ (yellow) containing the peptide sequence tucked 98 
into a small groove generated by the Fshr (Figure 1Civ).  We therefore predicted that 99 
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binding of an Ab to this sequence will inevitably block access of Fshβ to the small Fshr-100 
binding groove, thus preventing ligand-receptor interaction. 101 
Blockade of Fsh action by Ab was proven experimentally – the Ab reversed the 102 
Fsh-induced inhibition of Ucp1, a master regulator of adipocyte beiging9,10.  For this, we 103 
used immortalized dedifferentiated brown adipocytes from the ThermoMouse (hereafter 104 
termed Thermo cells), in which the Ucp1 promoter drives a Luc2-T2A-tdTomato reporter 105 
(Figure 1D)11.  Exogenous Fsh (30 ng/mL) inhibited Luc2 activity in serum-free medium 106 
(devoid of Fsh) irrespective of the Arb3 agonist CL316243 (10-7 M) (Figure 1D).  The Ab 107 
reversed this inhibition in a concentration-dependent manner, with complete reversal of 108 
the inhibition at 1 µg/mL Ab (Figure 1D). 109 
We explored whether concentrations of Ab achieved in plasma following injection 110 
were sufficient to block the inhibition of Ucp1 expression by Fsh.  Specifically, we asked 111 
whether a serum concentration of at least 1 µg/mL resulted from a single i.p. injection of 112 
100 µg Ab.  ELISA-based measurements in mice injected with Ab revealed a sharp 113 
increase in plasma Fsh Ab, measured as goat IgG, at 2 hours and levels remained at 114 
>10 µg/mL up to at least 24 hours (t1/2 = 25.6 hours) (Figure 1E).  Thus, circulating Ab 115 
concentrations post-injection were at least 10-fold higher than those required for the 116 
inhibition of Ucp1 by circulating Fsh. 117 
 118 
Fsh Ab Reduces Adiposity and Induces Thermogenesis in Mice on High Fat Diet 119 
Experiments using the Fsh Ab were carried out independently at the laboratories 120 
of M.Z. and C.J.R. (details in Extended Data Table 2).  Both labs concurrently examined 121 
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the effect of Fsh Ab or goat IgG, injected at 200 µg/day, i.p., on white adipose tissue 122 
(WAT) accumulation in wild type C56BL/6 mice that were pair-fed or allowed ad libitum 123 
access to a high fat diet.  Figure 2A shows equal food intake and no significant change 124 
in body weight with Ab treatment compared with goat IgG.  Quantitative NMR (qNMR) 125 
showed a reduction in total body fat and fat mass/total mass (FM/TM), and an increase 126 
in lean mass/total mass (LM/TM) in mice treated with Ab for ~8 weeks compared with 127 
IgG (Figure 2B).  Data were reproduced using both qNMR and dual energy X-ray 128 
absorptiometry (DXA) at 7 weeks, with no difference at 4 weeks (Figures 2B and 2C).  129 
DXA also showed a significant increase in bone mineral density at both 4 and 7 weeks 130 
(Figure 2D), in part explaining the increased lean mass in Ab-treated mice (c.f. Figure 131 
2B). 132 
Examination of the effect of Ab on distinct WAT compartments revealed highly 133 
significant decreases in adiposity, observed visually in coronal and transverse sections, 134 
on micro-computed tomography (µCT) of the entire thoracoabdominal cavity.  Total fat 135 
volume (TFV), subcutaneous fat volume (SFV) and visceral fat volume (VFV) were all 136 
significantly lower in Ab- versus IgG-treated group (Figure 2E).  Tissue weights, 137 
measured independently, showed decrements in inguinal (iWAT) and gonadal adipose 138 
tissue (gWAT) in Ab- compared with IgG-treated mice; no difference was observed in 139 
interscapular brown adipose tissue (BAT) (Figure 2F).  Liver and skeletal muscle 140 
sections likewise showed decreased Oil Red-O staining, indicative of reduced fat 141 
accumulation with Ab (Figure 2G).  Overall, despite equal food intake, the data show 142 
that Fsh inhibition with an Ab markedly reduces adiposity in all WAT compartments. 143 
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We performed indirect calorimetry using metabolic cages to determine the effects 144 
of Ab or IgG on whole body energy parameters, including O2 consumption (VO2), 145 
energy expenditure (EE), respiratory quotient (RQ), beam breaks (Xbreaks), walking 146 
distance and walking speed (Figure 2H).  Indicative of a potent thermogenic response, 147 
Ab-treated mice showed increases in VO2, EE, Xbreaks, and walking distance and 148 
speed at near-equal food intakes (Figure 2H).  These findings, together with the sharply 149 
reduced WAT, appear consistent with the induction of thermogenic beige adipose 150 
tissue. 151 
Glucose tolerance testing revealed no significant difference with Ab (Figure 2I).  152 
Consistent with this, plasma C-peptide levels were unchanged, as were plasma 153 
adiponectin and leptin levels (Figure 2J).  Circulating total cholesterol and free fatty 154 
acids were also not significantly different, but there was an increase in plasma 155 
triglycerides in Ab-treated mice (Figure 2K). 156 
Importantly, to probe whether the aforementioned anti-adiposity actions of the Ab 157 
were mediated solely through the Fsh axis in vivo, Fshr-deficient male mice were pair-158 
fed on high fat diet and treated similarly with Ab (Figure 2L).  Injection of wild type 159 
(Fshr+/+) mice with Ab evoked an expected reduction in fat mass and an increase in lean 160 
mass (qNMR) (Figure 2M, c.f. Figure 2B).  However, there was a graded reduction of 161 
this response with decreasing Fshr gene dosage, with no significant change in either 162 
parameter in Fshr-/- mice (Figure 2M).  The observation that the Fsh Ab failed to reduce 163 
body fat in Fshr–deficient mice provides proof of Ab specificity in vivo. 164 
 165 
 166 
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Fsh Ab Reduces Adiposity and Induces Thermogenesis in Ovariectomized Mice 167 
Fed a Normal Diet 168 
The perimenopausal transition is associated with increases in total body fat and 169 
decrements in energy expenditure and physical activity, all of which impact quality of 170 
life4.  This clinical phenotype is recapitulated in rodents post-ovariectomy, as well as in 171 
chronic hypoestrogenemic models, such as in Erα-/-, aromatase-/- and Fshr-/- mice6,12-14.  172 
While genetic Fshr deficiency does not seem to protect against the pro-adiposity effects 173 
of severe chronic hypoestrogenemia, we questioned whether acute suppression of Fsh 174 
action by an Fsh Ab can, through parallel mechanisms, not only attenuate bone loss7, 175 
but also reduce body fat and improve energy homeostasis.  Clinically, this is important 176 
during the late perimenopause, when the onset of central adiposity is accompanied by 177 
no change in estrogen and increases in Fsh levels2. 178 
We pair-fed mice with normal chow, so that their food intake was identical over 8 179 
weeks of treatment with Fsh Ab or IgG given i.p. post-ovariectomy or sham-operation 180 
(Figure 3A).  As with mice fed on a high fat diet (Figure 2A), total body weight remained 181 
unchanged (Figure 3A).  Ovariectomy expectedly resulted in a significant increase in 182 
plasma Fsh levels (Figure 3B).  To ensure that a higher circulating Fsh is blocked 183 
effectively, we used 200 or 400 µg/mouse of Ab in the ovariectomy group, as opposed 184 
to a 100 µg/mouse dose in sham-operated group.  Of note, despite Fsh being bound to 185 
our Ab, which detects a small Fshr-binding sequence (Figure 1B) and blocks Fsh action 186 
on the Fshr (Figures 1C and 1D), total plasma Fsh levels measured by ELISA were not 187 
significantly different between Ab- and IgG-treated groups (Figure 3B).  This confirms 188 
our previous data that the Fsh Ab does not in any significant way interfere with the 189 
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detection of Fsh by the ELISA kit7.  Also, as noted previously7, serum estrogen levels 190 
remained unchanged with Ab treatment (Figure 3B). 191 
Quantitative NMR showed a highly significant reduction in fat mass and FM/TM, 192 
with an increase in LM/TM with Fsh Ab in both the sham-operated and ovariectomized 193 
groups (Figure 3C, c.f. Figure 2B).  In separate experiments, ovariectomized and sham-194 
operated mice on normal chow ad libitum were subject to abdominal µCT.  Ab reduced 195 
TFV, VFV and SFV significantly, not only in the ovariectomized group, but also in sham-196 
operated mice (Figure 3D).  We also studied Ab effects on bone marrow adiposity using 197 
osmium µCT.  There was a clear decrease in marrow fat content (white) on visual 198 
inspection in Ab-treated groups compared with IgG controls (Figure 3E).  Quantitation 199 
revealed that, in mainly diaphyseal voxels of interest (VOI), ovariectomy predictably 200 
enhanced bone marrow adiposity (Figure 3E), and Ab decreased adiposity in all VOIs, 201 
both in sham-operated and ovariectomized mice compared with their respective IgG 202 
controls (Figure 3E).  Indirect calorimetry showed that the Fsh Ab not only enhanced 203 
resting and active EE, but also reduced RQ in both sham-operated and ovariectomized 204 
mice (Figure 3F).  There were no differences in plasma levels of glucose, cholesterol, 205 
triglyceride or free fatty acids between any of the groups (Figure 3G). 206 
It was most interesting, however, that sham-operated mice were equally 207 
responsive to Ab.  We thus repeated the study using 3 month-old C57BL/6 mice that 208 
were either pair-fed or reverse pair-fed with normal chow (see Methods for details).  Ab 209 
reduced fat mass and FM/TM (qNMR), as well as abdominal TFV, SFV and VFV (µCT) 210 
in both pair-fed and reverse pair-fed groups (Figure 4).  Importantly, despite their 211 
increase in caloric intake evident on reverse pair-feeding (Figure 4D), Ab-treated mice 212 
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showed a reduction in whole body and abdominal adiposity (Figures 4E, F).  No 213 
changes in total body weight were noted in any of the four groups (Figure 4A, D).  That 214 
Fsh inhibition by Ab in otherwise unperturbed mice resulted in reduced adiposity 215 
suggests that Fsh exerts a physiologic role in regulating body composition.   216 
 217 
Blocking Fsh Action on Adipocyte Fshrs Induces Ucp1 Expression 218 
Fshr cDNA and protein has been identified on fat tissue and adipocytes15,16, as 219 
well as by us, on osteoclasts and mesenchymal stem cells1,7.  The receptors have been 220 
shown to couple with a Gi protein, the activation of which was found to reduce cAMP 221 
levels1,15 and stimulate lipogenesis in 3T3.L1 cells15,16.  Here, we document Fshr protein 222 
expression not only on 3T3.L1 cells, but also on Thermo cells and adipocytes derived 223 
from murine mesenchymal stem cells (MSC-ad), as well as, importantly, on murine BAT 224 
and inguinal and visceral WAT (Figures 5A, B).  We have further Sanger sequenced 225 
full-length Fshr cDNA from MSC-ad and 3T3.L1 cells (Extended Data Figures 1, 2).  Of 226 
note, despite the absence of exon 2 in adipocytes derived from 3T3.L1 cells, the Fshr 227 
remains signaling-efficient and is fully functional, particularly in its ability to stimulate the 228 
core lipogenic gene program (Pparγ, Fas, Glut4, Lpl, Pref1, and Cebpd) (Figure 5C).  As 229 
further genetic evidence for Fsh effects on lipogenesis15, we show that mesenchymal 230 
stem cells from Fshr-/- mice display reduced Oil Red-O staining (Figure 5D). 231 
The mitochondrial protein Ucp1 has been widely recognized as a master 232 
regulator of white-to-beige transition of adipocytes17.  We explored whether Fsh 233 
inhibited induction of Ucp1 using Thermo cells, wherein Luc2 radiance is measured as a 234 
Ucp1 surrogate (ref. Figure 1D).  Experiments in the presence of serum, which contains 235 
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Fsh at 15-40 ng/mL (Figure 3B)18, showed that the Ab (100 ng/mL) induced Ucp1 (Luc2) 236 
expression, irrespective of the addition of a known Ucp1 inducer, the Arb3 agonist 237 
CL316243 (Figure 5E).  This stimulation was reversed by the further addition of Fsh (30 238 
ng/mL), establishing Fsh specificity (Figure 5E, c.f. Figure 1D).   239 
To examine the in vivo relevance of Ab effects on Ucp1 activation, we implanted 240 
Thermo cells into both flanks of 3 month-old nu/nu mice and injected IgG or Ab (100 241 
µg/mouse/day) for 2 months.  A dramatic increase in total (from both flanks) and 242 
average Luc2 radiance was noted upon injection of D-Luciferin (Figure 5F).  For 243 
confirmation, we examined tdTomato fluorescence (red) in iWAT sections.  Consistent 244 
with enhanced Luc2 radiance, Ab-treated mice showed a marked increase in tdTomato 245 
expression (Figure 5G).  Together, the data suggest that the Ab, by blocking Fsh action 246 
on the Fshr, activates Ucp1. 247 
 248 
Fsh Ab Induces Thermogenic Adipose Tissue and Triggers BAT Activation 249 
The induction of thermogenic adipose tissue, a.k.a. beiging, is typically 250 
characterized by the conversion of large lipid-rich adipocytes to significantly smaller, 251 
mitochondria-rich, energy-dissipating beige adipocytes that express Ucp1 and other 252 
mitochondrial genes17,19,20.  To determine whether the Fsh Ab induces thermogenic 253 
adipose tissue in vivo, wild type mice pair-fed on high fat diet or normal chow were 254 
injected with Ab or IgG in separate experiments.   255 
Consistent with the induction of adipocyte beiging, there was a significant 256 
decrease in adipocyte area and perimeter in hematoxylin-stained sections of inguinal fat 257 
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pads from Ab-treated mice (Figure 6A).  This was accompanied by a marked increase in 258 
Ucp1 immunostaining both in iWAT and BAT compartments (Figure 6B), as well as 259 
significant increases in the expression in iWAT of most brown fat genes, including Ucp1, 260 
Cox7, Cidea, Cox8a, Lhx8, Lep, Irs1, Cebpb, Fabp4, Vegfa, Cebpa, Retn, and Retnla 261 
(Figure 6C).  Increases were also noted in Ucp1, Cidea, Cebpa, and Vegfa expression 262 
in BAT at 1 month, commensurate with the early activation of the BAT gene program 263 
(Figure 6C). 264 
As a complementary in vivo test for early BAT activation and white-to-beige 265 
transition, and to examine the time courses of the respective effects, we imaged live 266 
ThermoMice (Figure 7), in which, as noted above (Figure 1D), a transgenic Ucp1 267 
promoter drives the Luc2-T2A-tdTomato reporter construct.  This allows Luc2 radiance 268 
monitored in vivo to serve as a surrogate for Ucp1 expression11.  ThermoMice were 269 
pair-fed on a high fat diet and injected with Ab or IgG (100 µg/mouse/day).  At 2 and 8 270 
weeks, we measured Luc2 radiance emitted from both dorsal and ventral surfaces for 271 
optimal visualization of interscapular BAT and inguinal WAT, respectively. 272 
Uninjected control mice showed no emitted radiance at either time point.  At 2 273 
weeks, there was a significant enhancement of Luc2 radiance emitted from 274 
interscapular BAT-rich region, and very little, if any, radiance from the iWAT-rich region 275 
(Figure 7A).  The BAT signal intensity was significantly enhanced at 8 weeks.  276 
Furthermore, there was a marked ~3-fold difference in BAT radiance in Ab- versus IgG-277 
treated mice (Figure 7B).  A similarly dramatic difference in iWAT radiance was noted 278 
between Ab- and IgG-treated groups, particularly noted on ventral sampling (Figure 7B).  279 
14 
 
The data together confirm that the Ab triggers early BAT activation, which is followed by 280 
a slower induction of beiging in the WAT compartment. 281 
Beiging is also associated with an increase in the density of functionally 282 
thermogenic mitochondria21,22.  To assess for increased mitochondrial density, we used 283 
the PhAMexcised mouse, in which a fluorescent protein from the octocoral 284 
Dendronephthya, Dendra2, is fused to a Cox8 mitochondrial targeting signal, yielding 285 
mito-Dendra2 (Figure 7C)23.  The expression of mito-Dendra2 thus reflects 286 
mitochondrial density.  We analyzed frozen sections of sWAT, vWAT and BAT from 287 
PhAMexcised mice treated with Ab or IgG (200 µg/mouse/day) for 4 weeks.  Compared 288 
with the IgG group, Ab-treated mice displayed a dramatic increase in mito-Dendra2 289 
fluorescence in all compartments, and smaller, more condensed, adipocytes in WAT 290 
compartments (Figure 7C).  This provided independent confirmation that Fsh inhibition 291 
induced mitochondria-rich, thermogenic adipose tissue. 292 
 293 
DISCUSSION 294 
The long-held belief that pituitary hormones act solely on master targets was first 295 
questioned when we documented G protein-coupled receptors for thyroid stimulating 296 
hormone (Tsh), Fsh, adrenocorticotrophic hormone (Acth), oxytocin and vasopressin on 297 
bone cells1,24-29.  These evolutionarily conserved hormones and their receptors are 298 
known to have primitive roles, and exist in invertebrate species as far down as 299 
coelenterates30.  It is not surprising therefore that each such hormone has multiple 300 
hitherto unrecognized functions in mammalian integrative physiology, and hence, 301 
becomes a potential target for therapeutic intervention. 302 
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Here, we show that blocking the access of Fsh to its receptor using an Ab results 303 
not only in increased bone mass, documented earlier7, but also in a remarkable 304 
reduction in adiposity in mice on a high fat diet or following ovariectomy.  This is 305 
coupled with the production of mitochondria-rich, thermogenic adipose tissue.  Notably, 306 
the anti-adiposity effects of Ab in vivo are abrogated in Fshr-/- mice, proving that the Ab 307 
acts by inhibiting Fsh action.  Furthermore, and importantly, that the Ab reduces 308 
adiposity in unperturbed mice on normal chow, suggests a physiologic role for Fsh in 309 
regulating body composition.  Underscoring Fsh action, and confirming prior data11,17, is 310 
the abundance of signaling-efficient Fshrs on adipocytes at all stages of differentiation.  311 
Fsh acts on these receptors to inhibit Ucp1 activation, and our Ab causes a dramatic, 312 
time-dependent increase in Ucp1 in both BAT and WAT compartments in vivo.  The 313 
latter action, best observed in the ThermoMouse, is associated with effects 314 
characteristic of thermogenic adipose tissue induction, namely alterations in cell 315 
morphology, gene expression, and mitochondrial density.   316 
Previous human studies and particularly the Study of Women’s Health Across the 317 
Nations (SWAN), an observational cohort of pre-, peri, and postmenopausal women 318 
followed over several years, showed that a phase of rapid bone loss ensues two to 319 
three years prior to the onset of menopause when FSH levels are rising and estrogen is 320 
relatively stable2,3.  SWAN also documented a better correlation of serum FSH with 321 
bone loss than declining estrogen levels3.  Furthermore, even after the onset of 322 
menopause, estrogen replacement therapy does not suppress serum FSH levels into 323 
the premenopausal range31, and women often continue to lose bone and further accrue 324 
visceral fat.  Our study supports these tenets, but more importantly provides 325 
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mechanistic insights into the clinical problem of peri- and postmenopausal weight gain 326 
and disrupted energy balance4,6. 327 
The use of agents to prevent weight gain or treat obesity, consisting mainly of 328 
those that reduce appetite or inhibit nutrient absorption, is compromised by issues of 329 
poor efficacy and unacceptable side effects19.  Thus, the therapeutic armamentarium for 330 
obesity pales in comparison with that of other public health hazards of similar or even 331 
lesser magnitudes, such as hypertension, diabetes or osteoporosis.  The focus 332 
therefore has been on targets that induce thermogenic adipose tissue, of which the 333 
Arb3 pathway with its downstream targets, prominently C/EBPβ and PRDM16, is most 334 
well characterized19,32-34.  However, agents against these putative targets are not 335 
sufficiently developed to be tested in people19.  Moreover, most such targets, such as 336 
C/EBPβ and PPARG, are expressed ubiquitously and during growth and development, 337 
which makes specificity an issue and off-target actions a possibility. 338 
Several considerations make a highly specific Fsh Ab unique.  First, it is a dual-339 
acting agent capable of impressively reducing adiposity and improving bone mass.  340 
Second, it induces thermogenic adipose tissue to improve whole body metabolism, a 341 
likely added benefit for postmenopausal women with disrupted energy homeostasis.  342 
Third, it has a powerful action in reducing visceral adiposity.  This is clinically very 343 
relevant considering that visceral adiposity is associated with an increased risk of 344 
metabolic syndrome, coronary artery disease, cancer and diabetes35.  These 345 
complications are thought to arise at least in part from the secretion of proinflammatory 346 
cytokines, including IL-6 and TNFα36.  Fsh blockade could thus be useful not only 347 
through its anti-adiposity and thermogenic actions, but also indirectly, via its inhibition of 348 
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Fsh-induced Tnfα production37.  Finally, and admittedly speculative, is our premise that 349 
an Fsh Ab may have a considerably limited off-target profile, mainly due to the restricted 350 
expression of the Fshr in gonads, bone and fat.   351 
  352 
18 
 
ACKNOWLEDGEMENTS 353 
Work at Icahn School of Medicine at Mount Sinai was supported by the National 354 
Institutes of Health (NIH) by grants R01 DK80459 (to M.Z. and L.S.), R01 AG40132 (to 355 
M.Z.), R01 AG23176 (to M.Z.), R01 AR06592 (to M.Z.) and R01 AR06066 (to M.Z. and 356 
N.G.A.).  A grant (# 81120108010) from National Science Foundation of China, Ministry 357 
of China (International Collaborative Grant to Z.B. and M.Z.) is also gratefully 358 
acknowledged.  The authors also acknowledge the Medical Research Council-359 
Technology (MRCT), London, UK, as well as Mount Sinai Innovation Partners (MSIP) 360 
for their collaboration on the actions of FSH on bone.  Work at Maine Medical Center 361 
Research Institute was supported by the NIH/NIGMS (P30 GM106391 and P30 362 
GM103392) and the NIH/NIDDK (R24 DK092759-06) to C.J.R.  The project was also 363 
supported by the Physiology Core Facility grant (P20 GM103465), COBRE in Stem Cell 364 
Biology and Regenerative Medicine, a grant supported by the National Institute of 365 
General Medical Sciences. 366 
 367 
DISCLOSURES 368 
M.Z. is a named inventor on a patent related to FSH and bone, owned by Icahn 369 
School of Medicine at Mount Sinai.  M.Z. will receive royalties and/or licensing fees per 370 
Mount Sinai policies, in case the patent is commercialized.  M.Z. also consults for 371 
Merck, Roche, Novartis, and a number of financial consulting platforms. 372 
  373 
19 
 
LEGENDS TO FIGURES 374 
Figure 1: Ab Blocks Fsh-Fshr Interaction at Physiologic Fsh Concentrations in 375 
Plasma.  Recombinant mouse Fsh (Fshα-Fshβ chimera, 2 µg) was passed through 376 
resin (Pierce Co-Immunoprecipitation Kit, 26149, Thermo Scientific) with immobilized 377 
Fsh Ab or goat IgG (A).  Elution (Eluate), flow-through (Flow), and consecutive wash 378 
fractions (Wash) were collected and immunoblotted, as shown, with a different Fsh Ab 379 
(Hf2).  The sequence of the Fshα-Fshβ chimera is shown (B).  Peptides from the 380 
trypsinized eluate matched by mass spectrometry are marked in red, with the linker 381 
peptide shown in red solid circles.  Ab was raised against human LVYKDPARPKIQK, 382 
which corresponds to mouse LVYKDPARPNTQK (green-filled circles) (B).  Crystal 383 
structure of the human FSH-FSHR complex (PDB id: 4AY9; FSHα not shown for clarity) 384 
indicates that the loop from the FSHβ subunit (yellow), containing the sequence 385 
LVYKDPARPKIQK (highlighted as sticks), tucks into a small groove generated by the 386 
FSHR (Ci).  Computational modelling of Fsh bearing the peptide sequence 387 
LVYKDPARPNTQK shows an identical binding mode (Cii).  Positively charged residues 388 
(blue) of the peptide surface complements the negatively charged residues (red) of the 389 
Fshr binding site, generating strong electrostatic interactions at the binding surface 390 
(arrow) (Ciii).  Given the small size of the groove (Civ), binding of Ab to the peptide 391 
sequence will completely shield Fshβ from entering the Fshr binding pocket.  That the 392 
Ab blocked Fsh action was confirmed experimentally using dedifferentiated brown 393 
adipocytes (Thermo cells), immortalized from the ThermoMouse (Jackson Labs).  The 394 
latter has a Luc2-T2A-tdTomato construct inserted at the initiation codon of the Ucp1 395 
gene11 (D).  Thermo cells retain BAT capacity and report Ucp1 activation using Luc2 as 396 
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reporter.  The effect of Fsh (30 ng/mL) and Fsh Ab (concentrations as noted) on Ucp1 397 
expression was tested in the absence of fetal bovine serum (that does not contain 398 
endogenous FSH) and the Arb3 agonist CL316243 (10-7 M).  Notably, 1 µg/mL Fsh Ab 399 
completely abolished the inhibitory effect of near-circulating levels of Fsh on Ucp1 400 
expression (D) (also see Figures 5E, F).  Statistics: comparisons by one-way ANOVA 401 
with posthoc Bonferroni correction; mean + SEM; *P<0.05, **P<0.01; in triplicate).  402 
ELISA-based measurements of goat IgG/Fsh Ab in mouse serum following single 403 
injection of Ab at 100 µg (i.p.) yielded serum Ab/IgG concentrations that were 20-fold 404 
higher than those required to inhibit Fsh action in vitro (t1/2 = 25.6 hours).  Mean + SEM, 405 
n = 3 mice/group (E). 406 
Figure 2: Fsh Antibody Markedly Reduces White Adipose Tissue and Induces 407 
Thermogenesis in Mice Fed on a High Fat Diet.  Daily injection of Fsh antibody (Ab) 408 
or goat IgG (200 µg/day/mouse) to 3 month-old male and/or female C57BL/6 mice pair-409 
fed on high fat diet (HFD, see Methods) for up to 8 weeks dramatically decreased fat 410 
mass, fat mass/total mass (FM/TM) and increased lean mass/total mass (LM/TM) on 411 
quantitative nuclear magnetic resonance (qNMR), without affecting total body weight (A, 412 
B).  Results were confirmed independently using qNMR (C) and dual energy X-ray 413 
absorptiometry (DXA) (D), the latter documenting reduced body fat at 7 weeks, and 414 
increased bone mineral density (BMD) at both 4 and 7 weeks.  Micro-computed 415 
tomography (µCT) of the thoracoabdominal cavity of mice with ad libitum access to high 416 
fat diet showed a similar marked reduction of total, subcutaneous and visceral fat 417 
volume (TFV, SFV and VFV, respectively) (E).  Representative coronal and transverse 418 
sections are shown, where visceral and subcutaneous fat is colored in red and yellow, 419 
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respectively (E).  Parallel experiments confirmed a reduction in the weight of white, 420 
namely inguinal (iWAT) and gonadal (gWAT) adipose fat pads, with no change in 421 
interscapular brown adipose tissue (BAT) weight (F).  Representative images of Oil 422 
Red-O-stained sections showing effects of Fsh Ab on fat accumulation in both liver and 423 
skeletal muscle (deep red staining) (G, liver, x20; muscle x40).  Indirect calorimetry 424 
using metabolic cages showed significant increases in O2 utilization (VO2), energy 425 
expenditure (EE), walking distance (walk), walking speed (walk speed), and beam 426 
breaks (Xbreaks), with no significant difference in CO2 production (VCO2), sleep hours 427 
or ad libitum food intake (not shown) with Ab versus IgG (H).  Glucose tolerance testing 428 
showed no difference between mice receiving IgG or Ab (AUC: area under curve) (I).  429 
Effect of Ab on plasma C-peptide, adiponectin, and leptin (J) levels, as well as on total 430 
cholesterol, triglycerides and free fatty acids (K).  Effects of Ab in reducing fat mass and 431 
increasing lean mass (%Δ over ~7 weeks) were near-abolished in Fshr-/- mice pair-fed 432 
on high fat diet, confirming that Ab action was Fsh-mediated (L, M).  Statistics: unpaired 433 
2-tailed Student’s t-test, assuming equal variance, corrected for Bonferroni, where 434 
necessary; *P<0.05, **P<0.01, or as shown; mean + SEM; n = 3-12 mice/group. 435 
 436 
Figure 3: Fsh Antibody Reduces Fat Accumulation in Ovariectomized Mice on 437 
Normal Chow.  Mice were ovariectomized or sham-operated and injected with Fsh 438 
antibody (Ab) or goat IgG (200 or 400 µg/day to sham-operated or ovariectomized mice, 439 
respectively) for 8 weeks while on normal chow (see Methods) (A).  Plasma Fsh levels 440 
detected by ELISA (Biotang, M7619) were higher in ovariectomized mice and were not 441 
altered with Ab treatment (B).  Fsh Ab did not affect plasma estrogen (E2) levels (ELISA, 442 
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Biotang, M7956) in sham-operated mice; levels mostly fell below assay detection limit in 443 
ovariectomized mice.  Pair-fed sham and ovariectomized groups showed significant 444 
decreases in fat mass, fat mass/total mass (FM/TM) and increases in lean mass/total 445 
mass (LM/TM) on quantitative nuclear magnetic resonance (qNMR) (C).  In separate 446 
studies, microcomputed tomography (µCT) of the thoracoabdominal cavity of sham-447 
operated and ovariectomized mice fed ad libitum with normal chow similarly showed a 448 
marked reduction of total, visceral and subcutaneous fat volume (TFV, VFV and SFV, 449 
respectively) (D).  Representative transverse sections are shown (pink–visceral fat, 450 
white–subcutaneous fat) (D).  There were also strong reductions in bone marrow fat 451 
with the Ab compared with IgG in both sham-operated and ovariectomized groups, 452 
noted on osmium µCT (marrow fat shown in white) (E).  Quantitation of marrow fat area 453 
(MA)/total volume (TV) at three voxels of interest (VOI) is shown (E).  Indirect 454 
calorimetry using metabolic cages was consistent with an Ab-induced thermogenic 455 
response, notably increases in energy expenditure (EE) (resting and/or active) and 456 
physical activity (wheel meters), with decreased respiratory quotient (RQ) (F).  Plasma 457 
glucose, total cholesterol, triglyceride and free fatty acids remained unchanged with Ab 458 
(G).  Statistics: Comparisons by unpaired 2-tailed Student’s t-test or one-way ANOVA, 459 
assuming equal variance, and corrected for Bonferroni where necessary; *P<0.05, 460 
**P<0.01, or as show; mean + SEM; n = 4-10 mice/group). 461 
 462 
Figure 4: Fsh Ab Reduces Body Fat in Mice Fed on Normal Chow.  Three month-463 
old C56BL/6 female mice were either pair-fed (A-C) or reverse pair-fed with normal 464 
chow (D-F) and injected with Fsh Ab or IgG (100 µg/mouse/day) for 7 and 5 weeks, 465 
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respectively.  For pair-feeding, the amount of chow consumed ad libitum by the IgG 466 
group was given to the Ab-treated group.  For the reverse pair-feeding, the Ab-treated 467 
group was allowed ad libitum access to food and the same amount of chow was given 468 
to IgG group, with the left-over chow measured to determine food intake of the IgG 469 
group (see Methods).  A significant increase in food intake by Ab-treated mice was 470 
noted in the reverse pair-feeding protocol (D).  Nonetheless, as with mice on a high fat 471 
diet (c.f. Figure 2B, C), in either feeding protocol, Ab caused a significant decrease in fat 472 
mass and fat mass/total mass (FM/TM) and increase in lean mass/total mass (LM/TM) 473 
on quantitative nuclear magnetic resonance (qNMR) (B and E), but without an effect on 474 
total body weight (A and D).  Micro-computed tomography (µCT) showed profound 475 
decrements in thoracoabdominal fat, visualized in representative coronal and transverse 476 
sections (red–visceral fat; yellow–subcutaneous fat), and upon quantitation of total, 477 
subcutaneous and visceral fat volumes (TFV, SFV and VFV, respectively) (C and F).  478 
Statistics: Unpaired 2-tailed Student’s t-test, assuming equal variance, and corrected for 479 
Bonferroni where necessary; *P<0.05, **P<0.01, or as shown (n = 4-5 mice/group). 480 
 481 
Figure 5: Ab Blocks Fsh Effects on Signaling-Efficient Fshrs to Activate Ucp1.  482 
Western immunoblotting shows the presence of Fsh receptors (Fshr) in 3T3.L1 cells, 483 
dedifferentiated brown adipocytes (Thermo cells), mesenchymal stem cell-derived 484 
adipocytes (MSC-adipocytes), and HeLa cells, but not on fibroblasts (293T) (A).  485 
Sanger sequencing confirmed full length Fshr cDNA in 3T3.L1 cells and MSC-486 
adipocytes (see Extended Data Figure 1).  Strong immunostaining with an anti-Fshr 487 
antibody (Lifespan Bioscience, LS-A4004) of sections of inguinal WAT and visceral 488 
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WAT (iWAT and vWAT, respectively) and BAT from C57BL/6 mice fed on normal chow 489 
(B).  Effect of Fsh (30 ng/mL) on the expression of core lipogenic genes, namely 490 
Ppparg, Fas, Glut4, Lpl, Pref1, Cebpd, and Lep in 3T3.L1 cells (C).  MSC-adipocytes 491 
from Fshr-/- mice showed reduced Oil Red-O staining (also quantitated calorimetrically in 492 
isopropanol cell extracts) versus cells from wild type littermates (D).  Luc2 activity was 493 
measured in extracts of Thermo cells (Figure 1D) (cultured in the presence of fetal 494 
bovine serum containing Fsh) in response to Ab (100 ng/mL) with/without the Arb3 495 
agonist CL316243 (10-7 M) (E).  The same cells (1.5x106) were implanted into each 496 
flank of nu/nu mice, which were fed on normal chow and injected with Ab (200 497 
µg/mouse/day) for 8 weeks, following which Luc2 radiance was quantitated post D-498 
Luciferin (10 µL/g) injection, using an IVIS luminescence imager (F) (see Methods).  For 499 
confirmation, sections of resected areas where cells had been implanted were 500 
examined for tdTomato fluorescence (x20) (G). 501 
 502 
Figure 6: Fsh Ab Induces Thermogenic Adipose Tissue in Mice on a High Fat Diet.  503 
Representative hematoxylin/eosin (H&E) stained sections of inguinal white adipose 504 
tissue (iWAT) showing white-to-beige transition of adipocytes upon daily injection for 8 505 
weeks of Fsh antibody (Ab) or goat IgG (200 µg/mouse) to 3 month-old C57BL/6 mice 506 
pair-fed on high fat diet.  Morphometry yielded highly significant reductions in adipocyte 507 
area and perimeter (A).  Immunolabeling for Ucp1 showed more intense staining in both 508 
iWAT and interscapular brown adipose tissue (BAT) (B) (representative sections, scale 509 
shown).  Shown also is the relative expression of the genes (names noted) in BAT 510 
versus WAT (Ci). Consistent with adipocyte beiging was an enhancement of BAT gene 511 
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expression (qPCR) in iWAT at 1 and/or 3 months (M) (Cii).  Statistics: Unpaired 2-tailed 512 
Student’s t-test, assuming equal variance, corrected for Bonferroni, where required; 513 
*P<0.05, **P<0.01 (qPCR, 3 biological replicates per group, each measured in 514 
triplicate). 515 
 516 
Figure 7: Fsh Ab Triggers Early Ucp1 Expression and Enhances Cellular 517 
Mitochondrial Density In Vivo.  In the ThermoMouse, a luciferase reporter construct, 518 
Luc2-T2A-tdTomato, is inserted into the Ucp1 locus on the Y-chromosome (see Figure 519 
1D)11.  Activation of Ucp1 expression leads to upregulation of Luc2, which can be 520 
quantitated in vivo by radiance measurements, using IVIS, following the injection of D-521 
Luciferin (10 µL/g) (see Methods).  3 month-old male ThermoMice were treated with Fsh 522 
antibody (Ab) or goat IgG (200 µg/mouse) for 2 (A) or 8 weeks (B) while being pair-fed 523 
on high fat diet, followed by D-Luciferin injection and radiance capture from dorsal 524 
and/or ventral surfaces of the entire body (total), inguinal white adipose tissue (WAT), 525 
and interscapular brown adipose tissue (BAT) regions.  Dramatic increases were noted 526 
in all parameters with the Ab compared with IgG or no treatment (Ctrl).  Of note is that, 527 
at two weeks, there was increased BAT, but not iWAT radiance, suggesting early 528 
activation of Ucp1 in BAT.  To assess mitochondrial density, we used the PhAMexcised 529 
mouse, wherein fluorescent dendra2 is selectively localized to mitochondria using a 530 
Cox8 mitochondrial targeting signal23.  Injection of Ab for 2 weeks in mice fed on normal 531 
chow dramatically increased dendra2 green fluorescence in the subcutaneous WAT 532 
(sWAT), visceral WAT (vWAT), and BAT compartments.  Statistics: Comparison of Ab 533 
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versus IgG by unpaired 2-tailed Student’s t-test, assuming equal variance; P values 534 
shown. 535 
 536 
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